Literature DB >> 20851183

Gene signatures in hepatocellular carcinoma (HCC).

Ourania M Andrisani1, Leo Studach, Philippe Merle.   

Abstract

Primary hepatocellular carcinoma (HCC) is a significant human cancer globally, with poor prognosis. New and efficacious therapy strategies are needed as well as new biomarkers for early detection of at-risk patients. In this review, we discuss select microarray studies of human HCCs, and propose a gene signature that has promise for clinical/translational application. This gene signature combines the proliferation cluster of genes and the hepatic cancer initiating/stem cell gene cluster for identification of HCCs with poor prognosis. Evidence from cell-based assays identifies the existence of a mechanistic link between these two gene clusters, involving the proliferation cluster gene polo-like kinase 1 (PLK1). We propose that PLK1 is a promising therapy target for HCC.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851183      PMCID: PMC3030925          DOI: 10.1016/j.semcancer.2010.09.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  66 in total

1.  Hepatitis B virus X protein increases the Cdt1-to-geminin ratio inducing DNA re-replication and polyploidy.

Authors:  Lova Rakotomalala; Leo Studach; Wen-Horng Wang; Gerald Gregori; Ronald L Hullinger; Ourania Andrisani
Journal:  J Biol Chem       Date:  2008-08-08       Impact factor: 5.157

2.  Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.

Authors:  Rossella Pellegrino; Diego F Calvisi; Sara Ladu; Volker Ehemann; Tommaso Staniscia; Matthias Evert; Frank Dombrowski; Peter Schirmacher; Thomas Longerich
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

Review 3.  Mechanisms of HBV-related hepatocarcinogenesis.

Authors:  Christine Neuveut; Yu Wei; Marie Annick Buendia
Journal:  J Hepatol       Date:  2010-01-07       Impact factor: 25.083

4.  CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop.

Authors:  Tao Li; Ji-Fan Hu; Xinwen Qiu; Jianqun Ling; Huiling Chen; Shukui Wang; Aiju Hou; Thanh H Vu; Andrew R Hoffman
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

5.  The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing.

Authors:  Francesca De Santa; Maria Grazia Totaro; Elena Prosperini; Samuele Notarbartolo; Giuseppe Testa; Gioacchino Natoli
Journal:  Cell       Date:  2007-09-06       Impact factor: 41.582

Review 6.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

Review 7.  Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

Review 8.  Translational microarray systems for outcome prediction of hepatocellular carcinoma.

Authors:  Norio Iizuka; Yoshihiko Hamamoto; Ryouichi Tsunedomi; Masaaki Oka
Journal:  Cancer Sci       Date:  2008-04       Impact factor: 6.716

9.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

View more
  28 in total

1.  Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.

Authors:  Leo L Studach; Stephan Menne; Stefano Cairo; Marie Annick Buendia; Ronald L Hullinger; Lydie Lefrançois; Philippe Merle; Ourania M Andrisani
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

2.  MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Authors:  Einas M Yousef; Daniela Furrer; David L Laperriere; Muhammad R Tahir; Sylvie Mader; Caroline Diorio; Louis A Gaboury
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

3.  Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication.

Authors:  Wen-Horng Wang; Leo L Studach; Ourania M Andrisani
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

4.  An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis.

Authors:  Maddalena Frau; Maria M Simile; Maria L Tomasi; Maria I Demartis; Lucia Daino; Maria A Seddaiu; Stefania Brozzetti; Claudio F Feo; Giovanni Massarelli; Giuliana Solinas; Francesco Feo; Ju-Seog Lee; Rosa M Pascale
Journal:  Cell Oncol (Dordr)       Date:  2012-03-21       Impact factor: 6.730

Review 5.  Preclinical models of non-alcoholic fatty liver disease.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Arun J Sanyal
Journal:  J Hepatol       Date:  2017-11-09       Impact factor: 25.083

6.  MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.

Authors:  C Wan; S Hou; R Ni; L Lv; Z Ding; X Huang; Q Hang; S He; Y Wang; C Cheng; X X Gu; G Xu; A Shen
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

7.  Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.

Authors:  Joan Fernando; Patricia Sancho; Conrado M Fernández-Rodriguez; José L Lledó; Laia Caja; Jean S Campbell; Nelson Fausto; Isabel Fabregat
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

8.  Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma.

Authors:  Xi-Hua Fu; Min Li; Hai-Bo Lou; Ming-Shou Huang; Chun-Long Liu
Journal:  Genet Res (Camb)       Date:  2016-11-11       Impact factor: 1.588

9.  Integrative genomic analysis of mouse and human hepatocellular carcinoma.

Authors:  Michelle Dow; Rachel M Pyke; Brian Y Tsui; Ludmil B Alexandrov; Hayato Nakagawa; Koji Taniguchi; Ekihiro Seki; Olivier Harismendy; Shabnam Shalapour; Michael Karin; Hannah Carter; Joan Font-Burgada
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-04       Impact factor: 11.205

Review 10.  Surveillance for gastrointestinal malignancies.

Authors:  Ashish K Tiwari; Heather S Laird-Fick; Ramesh K Wali; Hemant K Roy
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.